Browsing Tag
semaglutide
42 posts
NATCO Pharma (NSE: NATCOPHARM) wins CDSCO approval for semaglutide as FDA compliance risks recede at its API unit
NATCO Pharma Limited secures CDSCO approval for semaglutide as U.S. FDA risks ease. Find out what this means for growth, execution, and investors.
Lilly’s oral GLP-1 orforglipron sustains weight loss after injectables in pivotal Phase 3 trial
Lilly’s orforglipron helped patients maintain weight loss after injectable GLP-1s in a Phase 3 trial. Find out how this could reshape obesity treatment paths.
Is dose escalation the new edge in the obesity drug war? Why GLP-1 rivals are raising the ceiling on efficacy
High-dose GLP-1 drugs like 7.2 mg Wegovy are redefining obesity treatment in 2025. Find out how dose escalation is shifting efficacy expectations.
Can 7.2 mg Wegovy redefine the weight loss standard in obesity treatment?
Novo Nordisk files for FDA approval of 7.2 mg Wegovy with fast-track priority review. See what this higher dose means for the future of obesity treatment.
Crux raises $6.5m to help employers offer weight-loss and wellness drugs without insurance hurdles
Crux raises 6.5 million dollars to help employers offer affordable GLP-1 and lifestyle drug access. Learn how the platform plans to change benefits delivery.
Novo Nordisk’s Alzheimer’s treatment hopes crash as semaglutide fails to slow cognitive decline
Novo Nordisk’s GLP-1 pill failed in Alzheimer’s trials, raising questions on neurology diversification. Read what this means for its pipeline and stock.
Can GLP‑1 drugs tackle Alzheimer’s? Novo Nordisk’s setback raises doubts
Can Novo Nordisk challenge Eli Lilly’s GLP-1 lead with Alzheimer’s data? A crucial trial may redefine the future of semaglutide and reshape investor sentiment.
Can Camurus’ once-monthly semaglutide depot reshape the future of obesity and diabetes treatment?
Camurus reports positive Phase 1b results for CAM2056, a monthly semaglutide depot, showing 9.3% weight loss and strong A1c reduction. Read the full data.
Novo Nordisk taps Emcure Pharmaceuticals to launch Poviztra in India as second brand of Wegovy
Novo Nordisk partners with Emcure Pharmaceuticals to launch Poviztra, a second brand of Wegovy, in India. Discover how this could reshape obesity treatment access.
Ventyx Biosciences announces positive Phase 2 trial data for VTX3232 in obesity and cardiometabolic risk
Find out how Ventyx Biosciences’ VTX3232 is reshaping the obesity and cardiometabolic space through inflammation-targeted innovation.